The European Medicines Agency (EMA) announced it will review new safety data on the Alzheimer’s disease drug Leqembi (lecanemab). This follows a prior decision to recommend its use in the European ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback